IPR decision (Jun. 08, 2018):
|
AIA Review
|
Institution Date
|
Petitioner
|
Patent No.
|
Final Written Decision
|
|
IPR2017-00378; &
|
June 13, 2017
|
Merck Sharp & Dohme Corp
|
8,562,999
|
Claims 1–6, 10, 11, 14, 17, 19, 20 are unpatentable & claim 18 is patentable
|
|
IPR2017-00380
|
June 13, 2017
|
Merck Sharp & Dohme Corp
|
8,562,999
|
Claims 1–6, 10, 11, 14, 17, 19, 20 are unpatentable & claim 18 is patentable
|
|
IPR2017-00390
|
June 13, 2017
|
Merck Sharp & Dohme Corp
|
8,562,999
|
claims 7–9, 12, 13, 15, 16, 21, and 22 are unpatentable
|
US 8,562,999 claims formulation comprising (i) a pH buffered saline solution with pKa of about 3.5 to about 7.5, (ii) an aluminum salt and (iii) one or more polysaccharide-protein conjugates, wherein the formulation is comprised in a siliconized container means and inhibits aggregation induced by the siliconized container means.
This patent is related to Pfizer Inc.’s top-selling Prevnar 13 pneumonia vaccine.
Leave a Reply